Role of amyloid positron emission tomography (PET) imaging in the timely diagnosis of Alzheimer’s disease in patients with underlying depression or vitamin B12/Folate deficiency: feasibility study

Overview

2016 poster in https://doi.org/10.1016/j.jalz.2016.06.031 (added 23/04/2021) (published 01/07/2016) 2016 abstract in https://doi.org/10.1016/j.jalz.2016.06.1890 (added 23/04/2021) (published 01/07/2016)

Registry

who.int

Start Date

May 20, 2015

End Date

February 1, 2017

Last Updated

5 years ago

Study Type

Interventional

Sex

All

Sponsor

•1\. Patients aged \>40 referred to memory clinic
•2\. Presence of memory complaint suspicious of AD
•3\. Below normal scores on cognitive testing (CAMCOG, ACE III or sMMSE scores below the normal range)
•4\. Presence of specific co\-morbid illnesses known to affect cognition and to complicate the diagnosis of Alzheimer’s disease, namely depression and vitamin B12 deficiency
•5\. MRI and/or CT brain scanning done previously as part of routine diagnostic process

•1\. Evidence obtained from history, physical examination or investigations which clearly support the diagnosis of conditions such as vascular dementia, dementia with Lewy bodies and frontotemporal dementia
•2\. Lack of ability to give informed consent
•3\. Inability to undertake PET scanning or previous allergic reaction to injected investigative nuclear medicine tracers
•4\. Positive pregnancy test in premenopausal women and breastfeeding
•5\. Inability to undertake PET scanning